UCB Ventures Appoints Alicia Irurzun-Lafitte as Partner

Burgeoning Demand for MRI-guided Radiation Therapy Systems Market to Fuel Market Growth Thorough the COVID-19 Crisis Period

The relatively new technology for integrating magnetic resonance imaging (MRI) with radiation therapy is becoming increasingly prevalent, with revenues from the MRI-guided radiation therapy systems market exceeding US$ 220 Mn in 2018, according to a recent study by Fact.MR.

COVID-19 to Substantially Increase the Demand for 3D Printing Medical Devices Market from Key End-use Industry Sectors Unveils Fact.MR

The global 3D printing medical devices market is expected to exceed US$ 1,700 Mn in revenues by 2022-end, according to a recent research by Fact.MR.

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash.

UCB Ventures, the corporate venture arm of UCB Pharma, today announced that Alicia Irurzun-Lafitte will join UCB Ventures as Partner in Boston. Alicia brings 10 years of deal making experience, spanning business development transactions to early stage investments in biotech. She will work closely with the London and Brussels teams to source and support transactions in the US and beyond.

Alicia joins from M Ventures, the corporate ventures arm of Merck KGaA where she was instrumental in the expansion of its Healthcare Portfolio and was the US based representative since 2014. During her time at M Ventures, Alicia was closely involved in company creation with the Merck Spin-offs and she represented the fund on various boards. Alicia holds a Master of Research in Biopharmaceutical Sciences from Leiden University, the Netherlands.

“We are thrilled to have Alicia join our team,” said Erica Whittaker, Head of UCB Ventures. “Boston is a critically important biotech hub, and Alicia’s investment experience and network will add significantly to our efforts as we continue to build our investment portfolio.”

“I am delighted to join the UCB Ventures team and further contribute to the expansion of a new corporate venture fund that has a long-term commitment for high risk, high reward science,” said Alicia Irurzun-Lafitte. “Delivering impactful therapies to patients is deeply rooted in UCB culture, and its Venture Fund is one of the key enablers of this ambition.”



Subscribe to Medical Device News Magazine here.

Related Articles